CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: October 10, 2018
Result type: Reports
Project Number: SR0477-000
Product Line: Reimbursement Review

Generic Name: Tesamorelin

Brand Name: Egrifta

Manufacturer: Theratechnologies Inc.

Therapeutic Area: Lipodystrophy, HIV-infected patients

Indications: Lipodystrophy, HIV-infected patients

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: August 24, 2016

Recommendation Type: Do not reimburse